Nectar Lifesciences Q4 Results
- BSE: 532649
- NSE: NECLIFE
- ISIN: INE023H01027
- Sector: Biotechnology & Drugs
BSE
10.89
-0.48 (-4.22%)
-0.48 (-4.22%)Volume7.09 L
Updated: Fri 13 Mar, 2026 | 15:29:37
NSE
11.08-0.25 (-2.21%)
-0.25 (-2.21%)Volume1.65 M
Updated: Fri 13 Mar, 2026 | 15:25:28
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - Nectar Lifesciences Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 600.77 | -86.16 | 505170.31% | 407.59 | 47.39% |
| Depreciation/ Amortization | 15.77 | 0.06 | 22488.11% | 14.70 | 7.26% |
| Operating Income | -,170.07 | 86.16 | 150940.05% | 32.26 | 0.00% |
| Net Income | -,130.09 | 14.27 | 0.00% | 0.59 | 0.00% |
| Other Operating Expenses Total | 58.61 | 1.32 | 251441.20% | 61.02 | -3.96% |
| Net Income Before Taxes | -,187.67 | 56.60 | 0.00% | 11.11 | 0.00% |
| Total Revenue | 430.70 | 0.00 | 6836333.33% | 439.85 | -2.08% |
| Selling/ General/ Admin Expenses Total | 23.81 | 0.61 | 92176.74% | 23.94 | -0.57% |
| Diluted Normalized EPS | -5.84 | 0.46 | 0.00% | 0.03 | 0.00% |